TruScreen is pleased to announce the appointment of Mr. Reece O'Connell as an independent Non-Executive Director of the Company with effect from today's date.

TruScreen has today released its preliminary unaudited financial results for the financial year ended 31 March 2026.  

TruScreen is pleased to announce the appointment of Albatros Health Care LLC as its distributor in Uzbekistan and the commencement of a pilot clinical study in Tashkent to support market entry, with sales revenue potential NZD1.26m to the end of 2028.

TruScreen is pleased to advise that the Company has received firm commitments from both new and existing investors for an initial placement to institutional and other select investors of approximately 130 million shares at NZ$0.014 / A$0.012 per share to raise approximately NZ$1.82m / A$1.52m before costs.

TruScreen is pleased to announce the launch of an approximately NZ$2.943 million capital raising and issue of Shares today, comprising Placement, Options and Rights Offer.

TruScreen is collaborating with Nigeria’s Lagos State University Teaching Hospital (LASUTH) and Lagos State University College of Medicine (LASUCOM) for a Bill & Melinda Gates Foundation (Gates Foundation) grant application focused on cost-disruptive cervical cancer screening in Nigeria.

Unaudited FY2026 product sales revenue was in line with the guidance provided on 26 February 2026 at approximately NZ$2.4 million, representing an increase of 41% on FY2025. Total unaudited revenue for FY2026 is expected to be approximately NZ$2.8 million, slightly higher than the previous guidance and an increase of around 29% on FY2025.

TruScreen has submitted 3 proposals developed in partnership with leading global and regional health organisations, to deploy TruScreen's portable AI-enabled opto-electronic cervical screening technology across 14 high-burden countries in Africa, AsiaPacific, and Latin America with an addressable market of 1 billion women of screening age.

Mr Christopher Horn has informed the Company of his intention to retire as a non-executive director following the filing of the Company’s Preliminary Final results, expected to be on or around 31 May 2026.

An independent clinical study comparing TruScreen with Thinprep cytology test (TCT), and in combination with high-risk human papillomavirus (hr-HPV) testing, has been published and peer-reviewed in Journal of Sichuan University, confirming superiority of TruScreen + hr-HPV co-testing.

Spark+ Investor Relations Research has published a Research Flash Note on TruScreen Group Limited.

Results of the world's largest ever (n=14,982) study of opto-electronic cervical cancer screening, conducted by Chinese Obstetricians and Gynaecologists Association (COGA), have been published validating TruScreen as a superior primary cervical cancer screening tool over Liquid Based Cytology (LBC) and high-risk Human Papillomavirus (hrHPV) testing.

TruScreen Group Limited is pleased to provide an update on activities in key markets: Uzbekistan, Zimbabwe, Central Asia, Europe and China.

Recognizing the early warning signs of cervical cancer is critical for timely diagnosis and treatment. Although early stage cervical cancer frequently occurs without symptoms, awareness of the signs can help enable early detection and treatment to improve outcomes.

There is a significant global gap in cervical cancer prevention for older women. Reports from public health platforms in China and other parts of Asia reveal that large numbers of older women, especially those in rural or low-resource settings, have never participated in cervical screening programs. This gap places them at high risk for undiagnosed and advanced-stage cervical cancer, with limited treatment options and worse outcomes.

Leading Chinese medical publication Family Doctor confirms TruScreen’s efficacy as a cervical cancer screening tool for pregnant women, in a 2,000-patient study conducted at Guilin People’s Hospital.